



# SpheriCal® Calibration Platform Represents a Strategically Attractive Growth Opportunity

The SpheriCal® calibration platform represents a strategically attractive opportunity for Polymer Factory, supported by strong commercial traction, scalable operations, and significant market potential.

Polymer Factory already sells SpheriCal® to commercial customers, confirming that the platform is fully commercialized. Sales increased by approximately 150% during 2025 compared to the previous year. The instrument analysis industry continues to demonstrate attractive growth rates and strong profitability, while end customers within biotechnology and life science are driving increased demand for improved analytical performance—where calibration standards play a critical role.

SpheriCal® benefits from very high gross margins, strong intellectual property protection, and scalable manufacturing. Polymer Factory holds two patent families related to SpheriCal®, approved in five and three countries respectively, and the company's production processes and formulations are difficult to replicate. Importantly, the platform can be scaled efficiently without the need for significant capital investments.

During 2026, Polymer Factory expects to further expand the SpheriCal® platform through continued commercialization of calibration standards for several key application areas, including IM-MS, DMA-MS, ESI, LC-MS, and DESI-MS. In addition, the company is actively developing solutions for MALDI-MSI, a rapidly growing application area.

The market potential for calibration standards is substantial. Should Polymer Factory capture 20% of the global calibrant market, the estimated sales potential would amount to several billion SEK.

Key players in the field include Bruker, Agilent, Waters, Thermo Fisher, and Shimadzu, alongside leading universities and clinical institutions. Polymer Factory has established, to varying degrees, meaningful and growing collaborations with several of these stakeholders.

“We have all the key components in place and a solid structure that enables multiple commercial partnerships or potential M&A opportunities,” says Mats Wallnér, CEO of Polymer Factory.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-01-2026 20:05 CET.

## For more information, please contact:

Mats Wallnér, CEO

Phone: +46 (0) 70 951 95 06

E-mail: [mats.wallner@polymerfactory.com](mailto:mats.wallner@polymerfactory.com)

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at [www.polymerfactory.com](http://www.polymerfactory.com).